Biotech By Adam Feuerstein and Matthew Herper Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval
Biotech By Adam Feuerstein Drug makers grounding salespeople as coronavirus impact on business spreads
Biotech By Damian Garde and Adam Feuerstein How one company made $208 million on an untested coronavirus vaccine
Business By Scott Kirsner — Boston Globe The Engine at MIT is revving up the potential of ‘tough tech’
Biotech By Jonathan Saltzman — Boston Globe Thermo Fisher buys Dutch diagnostics company for $11.5 billion
Biotech By Adam Feuerstein Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease
Biotech By Adam Feuerstein With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption
Biotech By Jonathan Saltzman — Boston Globe Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison
Biotech By Adam Feuerstein Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk
Opinions Plus By Jonathan P. Gertler Why medtech is a different beast than biotech in the life sciences pack
Biotech By Adam Feuerstein With new combination drug data, Exelixis takes another shot at prostate cancer treatment
Adam's Take By Adam Feuerstein Investor impatience with Gilead reclamation project sparks acquisition chatter
Health Tech By Erin Brodwin Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so
Business By Matthew Herper Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
Exclusive By Erin Brodwin This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund
Biotech By Adam Feuerstein FDA approves the first treatment for peanut allergy, but commercial success is hardly assured
Biotech By Adam Feuerstein European regulators could take a harder line on the review of an Agios blood cancer drug
Adam's Take By Adam Feuerstein As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
Biotech By Jonathan Saltzman — Boston Globe Spring Bank scraps hepatitis R&D after patient dies in trial
Business By Adam Feuerstein Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
Biotech By Sharon Begley Three star scientists announce plan to solve biotech’s ‘missing women’ problem
Business By Andrew Joseph Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?
Biotech By Adam Feuerstein Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks
Biotech By Adam Feuerstein Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial
Biotech By Scott Kirsner — Boston Globe The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity
Pharma By Jonathan Saltzman — Boston Globe Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme